Insider Selling: Illumina (ILMN) Director Sells 250 Shares of Stock

Illumina (NASDAQ:ILMN) Director Frances Arnold sold 250 shares of the company’s stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $252.26, for a total value of $63,065.00. Following the transaction, the director now directly owns 10,189 shares of the company’s stock, valued at $2,570,277.14. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Frances Arnold also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Thursday, March 8th, Frances Arnold sold 250 shares of Illumina stock. The stock was sold at an average price of $241.50, for a total value of $60,375.00.

NASDAQ ILMN opened at $228.17 on Friday. The firm has a market cap of $33,540.99, a PE ratio of 56.90, a price-to-earnings-growth ratio of 3.01 and a beta of 0.89. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.99 and a quick ratio of 3.55. Illumina has a twelve month low of $167.98 and a twelve month high of $256.64.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.22. The business had revenue of $778.00 million during the quarter, compared to analysts’ expectations of $752.04 million. Illumina had a return on equity of 21.71% and a net margin of 26.56%. The company’s revenue was up 25.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.85 EPS. equities analysts expect that Illumina will post 4.59 earnings per share for the current year.

A number of institutional investors have recently made changes to their positions in ILMN. Nationwide Fund Advisors boosted its holdings in Illumina by 0.8% during the 3rd quarter. Nationwide Fund Advisors now owns 102,393 shares of the life sciences company’s stock valued at $20,397,000 after acquiring an additional 848 shares during the period. Canada Pension Plan Investment Board boosted its holdings in Illumina by 110.1% during the 3rd quarter. Canada Pension Plan Investment Board now owns 19,210 shares of the life sciences company’s stock valued at $3,827,000 after acquiring an additional 10,068 shares during the period. FDx Advisors Inc. purchased a new position in Illumina during the 3rd quarter valued at about $368,000. CIBC Asset Management Inc boosted its holdings in Illumina by 2.3% during the 3rd quarter. CIBC Asset Management Inc now owns 19,763 shares of the life sciences company’s stock valued at $3,937,000 after acquiring an additional 447 shares during the period. Finally, Toronto Dominion Bank boosted its holdings in Illumina by 12.0% during the 3rd quarter. Toronto Dominion Bank now owns 55,380 shares of the life sciences company’s stock valued at $11,031,000 after acquiring an additional 5,918 shares during the period. Institutional investors own 91.47% of the company’s stock.

Several research firms recently commented on ILMN. BTIG Research reissued a “hold” rating on shares of Illumina in a research note on Tuesday, January 16th. Wells Fargo raised Illumina from a “market perform” rating to an “outperform” rating and set a $205.00 price objective for the company in a research note on Tuesday, January 2nd. Evercore ISI began coverage on Illumina in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $250.00 price objective for the company. Canaccord Genuity reissued a “buy” rating and issued a $265.00 price objective (up from $255.00) on shares of Illumina in a research note on Wednesday, January 31st. Finally, Piper Jaffray reissued a “buy” rating and issued a $269.00 price objective on shares of Illumina in a research note on Tuesday, January 9th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and sixteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $241.39.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/08/illumina-inc-ilmn-director-frances-arnold-sells-250-shares-2.html.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply